| Literature DB >> 22874627 |
Pietro Amedeo Modesti1, Stefano Rapi, Mohamed Bamoshmoosh, Marzia Baldereschi, Luciano Massetti, Luigi Padeletti, Gian Franco Gensini, Dong Zhao, Dawood Al-Hidabi, Husni Al Goshae.
Abstract
CONTEXT: The prevalence of hypertension in developing countries is coming closer to values found in developed countries. However, surveys usually rely on readings taken at a single visit, the option to implement the diagnosis on readings taken at multiple visits, being limited by costs.Entities:
Year: 2012 PMID: 22874627 PMCID: PMC3425947 DOI: 10.1136/bmjopen-2012-001062
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of Hypertension and Diabetes in Yemen study participants
| Men | Women | |
|---|---|---|
| Participants, n | 5063 | 5179 |
| Living in urban location, n (%) | 2519 (49.8) | 2590 (50.0) |
| Age (years), mean (95% Cl) | 39.4 (39.0 to 39.9) | 39.2 (38.7 to 39.6) |
| 15–24 years, n (%) | 1016 (20.1) | 1058 (20.4) |
| 25–34 years, n (%) | 1020 (20.1) | 1047 (20.2) |
| 35–44 years, n (%) | 1008 (19.9) | 1021 (19.7) |
| 45–54 years, n (%) | 990 (19.6) | 1057 (20.4) |
| 55–69 years, n (%) | 1029 (20.3) | 996 (19.2) |
| Smokers (daily), n (%) | 1428 (28.2) | 458 (8.8) |
| Education (years), mean (95% Cl) | 7.7 (7.5 to 7.9) | 4.4 (4.2 to 4.5) |
| Illiterate, n (%) | 986 (19.5) | 2666 (51.5) |
| Can read and write, n (%) | 830 (16.4) | 375 (7.2) |
| Primary school, n (%) | 685 (13.5) | 661 (12.8) |
| Secondary school, n (%) | 832 (16.4) | 542 (10.5) |
| High school, n (%) | 774 (15.3) | 504 (9.7) |
| College or post, n (%) | 950 (18.8) | 428 (8.3) |
| Self-reported physical activity, n (%) | ||
| Sedentary | 914 (21.1) | 1465 (32.8) |
| Light to moderate | 2606 (60.1) | 2586 (57.9) |
| Vigorous | 814 (18.8) | 418 (9.4) |
| Self-reported fruit consumption, n (%) | ||
| ≤1 day/week | 2357 (46.7) | 2470 (47.8) |
| 2–4 day/week | 1947 (38.6) | 1962 (37.9) |
| ≥5 days/week | 744 (14.7) | 740 (14.3) |
| Self-reported vegetable consumption, n (%) | ||
| ≤1 day/week | 1101 (21.8) | 1040 (20.1) |
| 2–4 day/week | 1362 (26.9) | 1437 (27.8) |
| ≥5 days/week | 2597 (51.3) | 2692 (52.1) |
| Treated with antihypertensive drugs, n | 215 | 313 |
| Height (cm), mean (95% Cl) | 161.6 (161.4 to 161.8) | 153.1 to (152.9 to 153.3) |
| Weight (kg), mean (95% Cl) | 60.5 (60.1 to 60.9) | 56.9 (56.5 to 57.3) |
| Waist circumference (cm), mean (95% Cl) | 78.5 (78.1 to 78.9) | 80.0 (79.6 to 80.4) |
| Abdominal obesity, n (%) | 171 (3.4) | 1372 (26.5) |
| Body mass index (kg/m2), mean (95% Cl) | 23.1 (22.9 to 23.3) | 24.3 (24.1 to 24.5) |
| Overweight (25.0–29.9 kg/m2), n (%) | 1174 (23.2) | 1321 (25.5) |
| Obesity (≥30.0 kg/m2), n (%) | 349 (6.9) | 695 (13.4) |
| High cholesterol (≥5 mmol/l), n (%) | 593 (11.7) | 803 (15.5) |
| High triglycerides (≥1.7 mmol/l), n (%) | 2007 (39.6) | 1887 (36.4) |
| Diabetes | 257 (5.1) | 281 (5.4) |
| Interval between visits (days), mean (95% Cl) | 5.2 (5.2 to 5.3) | 5.5 (5.4 to 5.6) |
| First visit (mean, 95% Cl) | ||
| Systolic blood pressure (BP) (mm Hg) | 123.0 (122.6 to 123.4) | 122.7 (122.1 to 123.3) |
| Diastolic BP (mm Hg) | 76.9 (76.5 to 77.3) | 76.9 (76.7 to 77.1) |
| Heart rate (mm Hg) | 79.3 (79.1 to 79.5) | 2.2 (82.0 to 82.4) |
| Air temperature (°C) | 24.4 (24.2 to 24.6) | 24.3 (24.1 to 24.5) |
| Second visit (mean, 95% Cl) | ||
| Systolic BP (mm Hg) | 121.5 (121.1 to 121.9) | 120.6 (120.2 to 121.0) |
| Diastolic BP (mm Hg) | 76.2 (76.0 to 76.4) | 76.0 (75.8 to 76.2) |
| Heart rate (mm Hg) | 78.5 (78.3 to 78.7) | 81.1 (80.9 to 81.3) |
| Air temperature (°C) | 24.4 (24.2 to 24.6) | 24.2 (24.0 to 24.4) |
| Dipstik test ≥1+, n (%) | 339 (6.7) | 270 (5.2) |
| Self report of MI, stroke, POAD, n (%) | 47 (0.9) | 38 (0.7) |
Figure 1Diagnosis of hypertension (systolic blood pressure (BP) ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or self-reported use of antihypertensive drugs at the time of the interview) performed on the basis of measurements taken at the first visit (visit 1), at the second visit (visit 2) or both. The number of subjects with and without the condition and age-weighted rates (to the 15–69 years Yemen population) are reported.
Prevalence of hypertension, and awareness based on the first visit (visit 1), the second visit (visit 2) or both visits to the 10242 study participants
| Hypertension | Awareness among hypertensive subjects | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Both | Δ | Visit 1 | Visit 2 | Both | Δ | |
| Men (n=5063) | ||||||||
| Age decades, n (%) | ||||||||
| 15–24 years | 48 (4.7) | 42 (4.2) | 15 (1.5) | −68.1 | 4 (8.3) | 4 (9.5) | 4 (26.7) | 220.0 |
| 25–34 years | 82 (8.0) | 68 (6.7) | 41 (4.0) | −50.0 | 13 (15.9) | 13 (19.1) | 13 (31.7) | 100.0 |
| 35–44 years | 142 (14.1) | 101 (10.0) | 73 (7.2) | −48.6 | 20 (14.1) | 20 (19.8) | 20 (27.4) | 94.5 |
| 45–54 years | 263 (26.6) | 234 (23.7) | 188 (19.0) | −28.7 | 85 (32.3) | 85 (36.3) | 85 (45.2) | 39.9 |
| 55–69 years | 375 (36.5) | 315 (30.6) | 272 (26.4) | −27.5 | 118 (31.5) | 118 (37.5) | 118 (43.4) | 37.9 |
| Prevalence, % (95% Cl) | ||||||||
| Crude | 18.0 (16.9 to 19.1) | 15.0 (14.0 to 16.0) | 11.6 (10.8 to 12.5) | −35.3 | 26.4 (23.7 to 29.4) | 31.3 (28.1 to 34.7) | 39.9 (36.0 to 43.9) | 54.5 |
| Age standardised* | 16.2 (15.1 to 17.3) | 13.5 (12.5 to 14.4) | 10.2 (9.4 to 11.0) | −37.0 | – | – | – | – |
| Women (n=5179) | ||||||||
| Age decades, n (%) | ||||||||
| 15–24 years | 56 (5.3) | 40 (3.8) | 17 (1.6) | −69.7 | 1 (1.8) | 1 (2.5) | 1 (5.9) | 229.4 |
| 25–34 years | 97 (9.3) | 68 (6.5) | 46 (4.4) | −52.6 | 16 (16.5) | 16 (23.5) | 16 (34.8) | 110.9 |
| 35–44 years | 163 (16.0) | 136 (13.4) | 105 (10.3) | −35.6 | 54 (33.1) | 54 (39.7) | 54 (51.4) | 55.2 |
| 45–54 years | 371 (35.1) | 325 (30.8) | 285 (27.0) | −23.2 | 138 (37.2) | 138 (42.5) | 138 (48.4) | 30.2 |
| 55–69 years | 356 (35.7) | 297 (29.8) | 265 (26.6) | −25.6 | 133 (37.4) | 133 (44.8) | 133 (50.2) | 34.3 |
| Prevalence, % (95% Cl) | ||||||||
| Crude | 20.1 (19.1 to 21.2) | 16.7 (15.7 to 17.8) | 13.9 (12.9 to 14.8) | −31.2 | 33.8 (31.0 to 36.8) | 39.8 (36.6 to 43.1) | 46.9 (43.3 to 50.6) | 45.3 |
| Age standardised* | 18.3 (17.2 to 19.4) | 15.1 (14.1 to 16.1) | 12.3 (11.4 to 13.2) | −32.8 | – | – | – | – |
Δ=(percentage based on visit 1−percentage based on both visits)/percentage based on visit 1.
To the WHO standard population 2001.
Prevalence of treatment and control based on the first visit (visit 1), the second visit (visit 2), or both visits to the 10 242 study participants
| Current treatment among hypertensive subjects | Blood pressure control among treated subjects | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Both | Δ | Visit 1 | Visit 2 | Both | Δ | |
| Men (n=5063) | ||||||||
| Age decades, n (%) | ||||||||
| 15–24 years | 3 (6.3) | 3 (7.1) | 3 (20.0) | 220.0 | 1 (33.3) | 1 (33.3) | 1 (33.3) | – |
| 25–34 years | 10 (12.2) | 10 (14.7) | 10 (24.4) | 100.0 | 3 (30.0) | 2 (20.0) | 0 (0.0) | – |
| 35–44 years | 17 (12.0) | 17 (16.8) | 17 (23.3) | 94.5 | 7 (41.2) | 9 (52.9) | 7 (41.2) | – |
| 45–54 years | 73 (27.8) | 73 (31.2) | 73 (38.8) | 39.9 | 19 (26.0) | 23 (31.5) | 14 (19.2) | −26.3 |
| 55–69 years | 112 (29.9) | 112 (35.6) | 112 (41.2) | 37.9 | 19 (17.0) | 33 (29.5) | 15 (13.4) | −21.1 |
| Prevalence, % (95% Cl) | ||||||||
| Crude | 23.6 (20.9 to 26.5) | 28.3 (25.2 to 31.6) | 36.5 (32.7 to 40.5) | 54.5 | 22.8 (17.7 to 28.8) | 31.6 (25.8 to 38.1) | 17.2 (12.8 to 22.6) | −24.5 |
| Women (n=5179) | ||||||||
| Age decades, n (%) | ||||||||
| 15–24 years | 1 (1.8) | 1 (2.5) | 1 (5.9) | 229.4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| 25–34 years | 13 (13.4) | 13 (19.1) | 13 (28.3) | 110.9 | 8 (61.5) | 9 (69.2) | 6 (46.2) | −25.0 |
| 35–44 years | 50 (30.7) | 50 (36.8) | 50 (47.6) | 55.2 | 27 (54.0) | 29 (58.0) | 22 (44.0) | −18.5 |
| 45–54 years | 124 (33.4) | 124 (38.2) | 124 (43.5) | 30.2 | 36 (29.0) | 47 (37.9) | 31 (25.0) | −13.9 |
| 55–69 years | 125 (35.1) | 125 (42.1) | 125 (47.2) | 34.3 | 38 (30.4) | 41 (32.8) | 31 (24.8) | −18.4 |
| Prevalence, % (95% Cl) | ||||||||
| Crude | 30.0 (27.3 to 32.9) | 36.1 (33.0 to 39.4) | 43.6 (40.0 to 47.2) | 45.3 | 34.8 (29.7 to 40.2) | 40.3 (35.0 to 45.7) | 28.7 (24.0 to 34.0) | −17.4 |
Δ=(percentage based on visit 1—percentage based on both visits)/ percentage based on visit 1.
Rates of proteinuria and self-reported cardiovascular (CV) disease in Hypertension and Diabetes in Yemen participants found to be hypertensive at visit 1, at visit 2 or at both visits, in subjects finally excluded from the final diagnosis of hypertension (not confirmed), in normotensive subjects and in all participants
| Diagnosis | Subjects | DIPSTIK test ≥1+ | Self-report of CV disease | ||
|---|---|---|---|---|---|
| n | n | % (95% Cl) | n | % (95% Cl) | |
| Hypertension at visit 1 | 1938 | 153 | 7.9 (6.8 to 9.2) | 58 | 3.0 (2.3 to 3.8) |
| Hypertension at visit 2 | 1614 | 141 | 8.7 (7.5 to 10.2) | 55 | 3.4 (2.6 to 4.4) |
| Hypertension at both | 1296 | 123 | 9.5 (8.0 to 11.2) | 53 | 4.1 (3.1 to 5.3) |
| Not confirmed | 959 | 48 | 5.0 (3.8 to 6.6) | 7 | 0.7 (0.0 to 1.5) |
| Normotensives | 7769 | 438 | 5.6 (5.1 to 6.2) | 25 | 0.3 (0.2 to 0.5) |
| All participants | 10 025 | 609 | 6.1 (5.6 to 6.6) | 85 | 0.8 (0.7 to 1.0) |
Figure 2Factors associated with confirmation of hypertension diagnosis (systolic blood pressure (BP) ≥140 mm Hg and/or diastolic BP ≥90 mm Hg at both visits) at multiple logistic regression analysis including only non-treated subjects (n=1396). Results are expressed as OR with 95% Cl.
Cardiovascular risk distribution among the 9926 adult subjects investigated in the Hypertension and Diabetes in Yemen study based on the results first visit (visit 1), or both visits
| After visit 1 | After two visits | Δ | |||||
|---|---|---|---|---|---|---|---|
| Risk categories | n= | Crude (%) | Age weighted, % (95% Cl) | n | Crude | Age weighted, % (95% Cl) | n |
| Average | 2246 | 22.6 | 30.3 (28.9 to 31.6) | 2326 | 23.4 | 31.3 (29.9 to 32.7) | 128 851 |
| Low | 3387 | 34.1 | 33.7 (32.4 to 35.0) | 3495 | 35.2 | 34.1 (32.8 to 35.4) | 48 207 |
| Moderate | 2234 | 22.5 | 20.3 (19.3 to 21.3) | 2281 | 23.0 | 20.7 (19.7 to 21.7) | 52 613 |
| High | 1206 | 12.1 | 8.2 (7.7 to 8.7) | 1033 | 10.4 | 6.6 (6.1 to 7.1) | −190 741 |
| Very high | 853 | 8.6 | 7.5 (6.9 to 8.1) | 792 | 8.0 | 7.2 (6.6 to 7.8) | −36 523 |
Δ=estimated difference between Yemen subjects attributed to the risk category on the basis of blood pressure (BP) measurements taken at the first visit and those attributed to the same class on the basis of average of BP measurements taken at both visits (subjects allocated at visit 1−subjects allocated after two visits).
Figure 3Blood pressure (BP) and cardiovascular risk stratification of Hypertension and Diabetes in Yemen participants according to the European Society of Hypertension/European Society of Cardiology chart using average BP values at visit1 and at both visits.